<DOC>
	<DOCNO>NCT01877655</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ASP0113 compare placebo measure primary composite endpoint overall mortality CMV end organ disease ( EOD ) 1 year post-transplant . Safety ASP0113 subject undergoing allogeneic HCT also evaluate .</brief_summary>
	<brief_title>A Study Evaluate Therapeutic Vaccine , ASP0113 , Cytomegalovirus ( CMV ) -Seropositive Recipients Undergoing Allogeneic , Hematopoietic Cell Transplant ( HCT )</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject CMVseropositive HCT recipient Subject plan undergo either follow : Sibling Donor Transplant Unrelated Donor Transplant Subject one follow underlying disease : Acute myeloid leukemia ( AML ) Acute lymphoblastic leukemia ( ALL ) Acute undifferentiated leukemia ( AUL ) Acute biphenotypic leukemia Chronic myelogenous leukemia ( CML ) Chronic lymphocytic leukemia ( CLL ) . A defined myelodysplastic syndrome ( ) ( MDS ) Primary secondary myelofibrosis Lymphoma ( include Hodgkin 's ) Subject active CMV disease infection receive treatment active CMV disease infection within 3 month ( 90 day ) prior transplant Subject modify hematopoietic cell transplant comorbidity index ( HCTCI ) score â‰¥ 4 Subject receive prior HCT residual Chronic Graftversushost Disease ( cGVHD ) Subject schedule cord blood transplant haploidentical transplant Subject platelet count le 50,000 mm3 within 3 day prior randomization ( platelet transfusion allow ) Subject aplastic anemia multiple myeloma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ASP0113</keyword>
	<keyword>Cytomegalovirus ( CMV )</keyword>
	<keyword>Hematopoietic Cell Transplant ( HCT )</keyword>
</DOC>